These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 12221168)

  • 1. Interferon beta1a and depression in secondary progressive MS: data from the SPECTRIMS Trial.
    Patten SB; Metz LM;
    Neurology; 2002 Sep; 59(5):744-6. PubMed ID: 12221168
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Benefit of interferon beta-1a on MSFC progression in secondary progressive MS.
    Cohen JA; Cutter GR; Fischer JS; Goodman AD; Heidenreich FR; Kooijmans MF; Sandrock AW; Rudick RA; Simon JH; Simonian NA; Tsao EC; Whitaker JN;
    Neurology; 2002 Sep; 59(5):679-87. PubMed ID: 12221157
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized controlled trial of interferon-beta-1a in secondary progressive MS: MRI results.
    Li DK; Zhao GJ; Paty DW;
    Neurology; 2001 Jun; 56(11):1505-13. PubMed ID: 11402107
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multicentre, randomised, double blind, placebo controlled, phase III study of weekly, low dose, subcutaneous interferon beta-1a in secondary progressive multiple sclerosis.
    Andersen O; Elovaara I; Färkkilä M; Hansen HJ; Mellgren SI; Myhr KM; Sandberg-Wollheim M; Soelberg Sørensen P
    J Neurol Neurosurg Psychiatry; 2004 May; 75(5):706-10. PubMed ID: 15090564
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The use of rebif in the Moscow Municipal Multiple Sclerosis Center].
    Popova EV; Boĭko AN; Davydovskaia MF; Demina TL; Lashch NIu; Popova NF; Khachanova NV; Shchur SG; Gusev EI
    Zh Nevrol Psikhiatr Im S S Korsakova; 2011; 111(2 Pt 2):68-71. PubMed ID: 21916159
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Depression in multiple sclerosis associated with interferon beta-1a (Rebif).
    Pandya R; Patten S
    Can J Psychiatry; 2002 Sep; 47(7):686. PubMed ID: 12355685
    [No Abstract]   [Full Text] [Related]  

  • 7. Extended observations on MS patients treated with IM interferon-beta1a (Avonex): implications for modern MS trials and therapeutics.
    Jacobs L; Rudick R; Simon J
    J Neuroimmunol; 2000 Jul; 107(2):167-73. PubMed ID: 10854652
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single-use autoinjector for peginterferon-β1a treatment of relapsing-remitting multiple sclerosis: safety, tolerability and patient evaluation data from the Phase IIIb ATTAIN study.
    Seddighzadeh A; Hung S; Selmaj K; Cui Y; Liu S; Sperling B; Calabresi PA
    Expert Opin Drug Deliv; 2014 Nov; 11(11):1713-20. PubMed ID: 25073663
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized controlled trial of interferon- beta-1a in secondary progressive MS: Clinical results.
    Secondary Progressive Efficacy Clinical Trial of Recombinant Interferon-Beta-1a in MS (SPECTRIMS) Study Group
    Neurology; 2001 Jun; 56(11):1496-504. PubMed ID: 11402106
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interferon treatment may trigger primary headaches in multiple sclerosis patients.
    La Mantia L; D'Amico D; Rigamonti A; Mascoli N; Bussone G; Milanese C
    Mult Scler; 2006 Aug; 12(4):476-80. PubMed ID: 16900761
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Haematological effects of interferon-beta-1a (Rebif) therapy in multiple sclerosis.
    Rieckmann P; O'Connor P; Francis GS; Wetherill G; Alteri E
    Drug Saf; 2004; 27(10):745-56. PubMed ID: 15350158
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A single-center, randomized, double-blind, placebo-controlled study of interferon beta-1b on primary progressive and transitional multiple sclerosis.
    Montalban X; Sastre-Garriga J; Tintoré M; Brieva L; Aymerich FX; Río J; Porcel J; Borràs C; Nos C; Rovira A
    Mult Scler; 2009 Oct; 15(10):1195-205. PubMed ID: 19797261
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interferon beta-1b (betaseron/betaferon) is well tolerated at a dose of 500 microg: interferon dose escalation assessment of safety (IDEAS).
    Gottesman MH; Friedman-Urevich S
    Mult Scler; 2006 Jun; 12(3):271-80. PubMed ID: 16764339
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [PRISMS Study. Interferon-beta 1a (Rebif) in relapsing multiple sclerosis].
    Hartung HP; Flachenecker P; Weilbach FX; Rieckmann P
    Nervenarzt; 1999 Feb; 70(2):182-5. PubMed ID: 10098156
    [No Abstract]   [Full Text] [Related]  

  • 15. Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial.
    Comi G; De Stefano N; Freedman MS; Barkhof F; Polman CH; Uitdehaag BM; Casset-Semanaz F; Hennessy B; Moraga MS; Rocak S; Stubinski B; Kappos L
    Lancet Neurol; 2012 Jan; 11(1):33-41. PubMed ID: 22146409
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatic reactions during treatment of multiple sclerosis with interferon-beta-1a: incidence and clinical significance.
    Francis GS; Grumser Y; Alteri E; Micaleff A; O'Brien F; Alsop J; Stam Moraga M; Kaplowitz N
    Drug Saf; 2003; 26(11):815-27. PubMed ID: 12908850
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Course of depression during the initiation of interferon beta-1a treatment for multiple sclerosis.
    Mohr DC; Likosky W; Dwyer P; Van Der Wende J; Boudewyn AC; Goodkin DE
    Arch Neurol; 1999 Oct; 56(10):1263-5. PubMed ID: 10520943
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interferon beta-1a-induced depression and suicidal ideation in multiple sclerosis.
    Lana-Peixoto MA; Teixeira AL; Haase VG
    Arq Neuropsiquiatr; 2002 Sep; 60(3-B):721-4. PubMed ID: 12364937
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interferon beta-1b and secondary progressive multiple sclerosis: licence extension. Useful, but further assessment required.
    Prescrire Int; 2000 Aug; 9(48):110-1. PubMed ID: 11067719
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interferon beta-1 a and depression in relapsing-remitting multiple sclerosis: an analysis of depression data from the PRISMS clinical trial.
    Patten SB; Metz LM
    Mult Scler; 2001 Aug; 7(4):243-8. PubMed ID: 11548984
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.